Yoshiaki Egashira1, Saurabh Singh2, Steve Bandula2, Rowland Illing3. 1. Interventional Oncology Service, University College London Hospital, London, United Kingdom; Department of Radiology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. Electronic address: egashiy2@cc.saga-u.ac.jp. 2. Centre for Medical Imaging, University College London, London, United Kingdom. 3. Interventional Oncology Service, University College London Hospital, London, United Kingdom.
Abstract
PURPOSE: To evaluate the safety and efficacy of percutaneous high-energy microwave ablation (MWA) for the treatment for pulmonary tumors. MATERIALS AND METHODS: A retrospective review was undertaken of 44 patients (21 men, 23 women; median age, 66 y; range, 17-89 y) who underwent 62 sessions of high-energy MWA for 87 pulmonary tumors at a single tertiary referral center between June 2012 and June 2014. Primary tumor origin was sarcoma (n = 23), colorectal (n = 16), lung (n = 2), esophageal (n = 1), breast (n = 1), and bladder (n = 1). Median tumor size was 12 mm (range, 6-45 mm). Technical success was recorded contemporaneously, complication rate at 30 days was recorded prospectively, and technique effectiveness was assessed by longitudinal follow-up CT scan. RESULTS: Primary technical success was achieved in 94% of ablation sessions. The median follow-up interval was 15 months (range, 6.2-29.5 mo) during which time local tumor progression was observed in two of 87 tumors (technique effectiveness 98%). Pneumothorax requiring chest tube insertion occurred in 19%; delayed pneumothorax occurred in four patients. No hemoptysis, infection, or other complications were recorded. CONCLUSIONS: High-energy MWA is safe and effective for the destruction of lung tumors.
PURPOSE: To evaluate the safety and efficacy of percutaneous high-energy microwave ablation (MWA) for the treatment for pulmonary tumors. MATERIALS AND METHODS: A retrospective review was undertaken of 44 patients (21 men, 23 women; median age, 66 y; range, 17-89 y) who underwent 62 sessions of high-energy MWA for 87 pulmonary tumors at a single tertiary referral center between June 2012 and June 2014. Primary tumor origin was sarcoma (n = 23), colorectal (n = 16), lung (n = 2), esophageal (n = 1), breast (n = 1), and bladder (n = 1). Median tumor size was 12 mm (range, 6-45 mm). Technical success was recorded contemporaneously, complication rate at 30 days was recorded prospectively, and technique effectiveness was assessed by longitudinal follow-up CT scan. RESULTS: Primary technical success was achieved in 94% of ablation sessions. The median follow-up interval was 15 months (range, 6.2-29.5 mo) during which time local tumor progression was observed in two of 87 tumors (technique effectiveness 98%). Pneumothorax requiring chest tube insertion occurred in 19%; delayed pneumothorax occurred in four patients. No hemoptysis, infection, or other complications were recorded. CONCLUSIONS: High-energy MWA is safe and effective for the destruction of lung tumors.
Authors: Thomas J Vogl; Andrei Roman; Nour-Eldin A Nour-Eldin; Wolfgang Hohenforst-Schmidt; Iliana Bednarova; Benjamin Kaltenbach Journal: Diagn Interv Radiol Date: 2018 Jan-Feb Impact factor: 2.630
Authors: I Kurilova; A Gonzalez-Aguirre; R G Beets-Tan; J Erinjeri; E N Petre; M Gonen; M Bains; N E Kemeny; S B Solomon; C T Sofocleous Journal: Cardiovasc Intervent Radiol Date: 2018-05-29 Impact factor: 2.740
Authors: Hiroshi Kodama; Eisuke Ueshima; Song Gao; Sebastien Monette; Lee-Ronn Paluch; Kreg Howk; Joseph P Erinjeri; Stephen B Solomon; Govindarajan Srimathveeravalli Journal: Int J Hyperthermia Date: 2018-04-18 Impact factor: 3.914
Authors: Shanda H Blackmon; Rosalie M Sterner; Patrick W Eiken; Thomas J Vogl; Bradley B Pua; Jeffrey L Port; Damian E Dupuy; Matthew R Callstrom Journal: J Thorac Dis Date: 2021-12 Impact factor: 2.895